Legacy

+41%

est. 2Y upside i

HealthcareSeries B

Legacy helps you test, improve, and freeze your sperm

Rank

#1145

Sector

Fertility Technology / Digital Health

Est. Liquidity

~3Y

Data Quality

Data: Medium

Legacy offers a moderate equity upside with 41% expected return over 2 years, but high uncertainty due to missing valuation data.

Last updated: July 21, 2026

Bull (25%)+88%

If Legacy goes public or gains market leadership, revenue multiple could expand to 7x, yielding 135% upside pre-dilution, or 88% after 20% dilution.

Base (50%)+48%

Convergence to public comp multiples of 5.5x on projected $124M revenue gives 85% pre-dilution upside, netting 48% after dilution.

Bear (25%)-19%

Multiple compression to 3x on slower growth yields 1% pre-dilution upside, but 20% dilution leads to -19% return.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Funding Intensity

1640%

Total funding of $60.5M represents 16.4% of estimated entry valuation, making preference overhang moderate but not severe.

Dilution Risk

moderate

Given profitability, dilution risk is moderate; a future round could dilute 15-25%.

Secondary Liquidity

none

No secondary market exists; liquidity likely tied to IPO or acquisition.

Questions to Ask at the Interview

Strategic questions based on Legacy's data — designed to show you've done your homework.

1
“How does Legacy's unit economics compare to other digital health companies given its high gross margin of 55%?”
2
“What is the strategy to scale beyond military and insurance partnerships into direct-to-consumer?”
3
“How does the equity structure (preferred vs common) and potential dilution from future rounds affect employee ownership?”

Our model estimates +41% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.